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A B S T R A C T
Aims: The microsomal triglyceride transport protein (MTTP) is critical for assembly and secretion of apolipo-
protein B (apoB)-containing lipoproteins and is most abundant in the liver and intestine. Surprisingly, MTTP is
also expressed in the heart. Here we tested the functional relevance of cardiac MTTP expression.
Materials and methods: We combined clinical studies, advanced expression analysis of human heart biopsies and
analyses in genetically modified mice lacking cardiac expression of the MTTP-A isoform of MTTP.
Results: Our results indicate that lower cardiac MTTP expression in humans is associated with structural and
perfusion abnormalities in patients with ischemic heart disease. MTTP-A deficiency in mice heart does not affect
total MTTP expression, activity or lipid concentration in the heart. Despite this, MTTP-A deficient mice displayed
impaired cardiac function after a myocardial infarction. Expression analysis of MTTP indicates that MTTP ex-
pression is linked to cardiac function and responses in the heart.
Conclusions: Our results indicate that MTTP may play an important role for the heart function in conjunction to
ischemic events.
1. Introduction
The microsomal triglyceride transport protein (MTTP) is a hetero-
dimer consisting of a unique MTTP subunit and a protein disulfide
isomerase (PDI) subunit [1]. The MTTP subunit belongs to a lipid
transfer protein family which also includes apoB, insect apolipophorin
II/I, and the egg yolk precursor vitellogenin [1]. The MTTP subunit
preferentially transfers neutral lipids compared with charged lipids and
is most abundant in the liver and intestine [2,3]. However, it is capable
of binding and transferring a wide variety of lipid molecules [1]. PDI is
a ubiquitously enzyme that catalyzes the formation and breakage of
disulfide bonds within proteins as they fold. The function of PDI in
MTTPMTTP is still uncertain but it has been proposed to maintain
MTTP in a soluble form [1].
Three splice variants of MTTP (MTTP-A, eB and eC) have been
identified to date [4–7]. All three isoforms display lipid transfer activity
but differ in their tissue distribution. MTTP-A is mostly found in the
liver and intestine where it localizes mainly in the endoplasmic re-
ticulum, MTTP-B in adipose tissue and natural killer T cells where it is
localized mainly in the Golgi apparatus, and MTTP-C in tissues such as
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liver and brain [4–7]. Intriguingly, all three isoforms are also expressed
in the heart [4,5,8]. Importantly, in humans only MTTP-A and MTTP-C
are translated into protein but the MTTP-C translation is strongly in-
hibited by regulatory elements within its 5′-UTR [4]. Thus, the MTTP-C
protein levels are approximately 10% of MTTP-A [9]. However, there is
no major difference in lipid transfer activity between MTTP-A and
MTTP-C [4].
In the liver and small intestine, MTTP is critical for the formation of
apoB-containing triglyceride-rich lipoproteins. Its role in other tissues is
still unclear, but some information has emerged. For example, MTTP is
important for the immune response [10]. In antigen presenting cells,
MTTP is critical fpr biosynthesis of the lipid antigen presenting protein
CD1 [11], andMttp-deficient mice are unable to activate natural killer T
(NKT) cells [10,11]. In adipocytes, MTTP has been linked to lipid
droplet formation [10]. In the heart, expression of MTTP is critical for
cardiac synthesis and secretion of apoB-containing lipoproteins
[12–14]. The physiological relevance of cardiac lipoprotein secretion is
still unclear but it has been shown that cardiac lipid accumulation is
linked to impaired cardiac contractility and conductivity [15] and heart
failure [16,17], and increased cardiac secretion of apoB-containing li-
poproteins has been proposed to play an important role in unloading
potentially toxic lipids that accumulate in cardiomyocytes under is-
chemic conditions [18,19]. In support of this hypothesis, over-
expression of human apoB in transgenic mice has been shown to reduce
cardiac remodeling and hypertrophy after a myocardial infarction and
to protect against lipotoxic cardiomyopathy [20,21]. In Drosophila
cardiomyocyte MTTP has been shown to be the main regulator of the
whole-body lipid metabolism since cardiomyocyte-derived apoB-lipo-
proteins are the main source of circulating lipids [22].
In humans, three common polymorphisms of MTTP have been de-
scribed that are in complete allelic association (D′=1, r2= 1);
−493G > T (rs1800591), −164 T > C (rs1800804), and Ile128Thr
(rs3816873) [1]. The minor C allele at position −164 has been asso-
ciated with decreased MTTP transcription compared with the major T
allele and the net effect of minor alleles of these two promoter poly-
morphisms −493G > T and −164 T > C is decreased expression
mediated by allele-specific binding of transcription factors to the
−164 T > C polymorphism [24].
Others and we have earlier reported that the −493G > T poly-
morphisms associated with increased risk of ischemic heart disease
independent of plasma lipids [24,25]. However, different results have
been reported [26–30]. The underlying mechanism is unclear but a
study in mice has shown that failure to upregulate Mttp expression in
response to increased fatty acid availability increases cardiac lipid ac-
cumulation and reduces heart function [31].
To further our understanding of the biological relevance of cardiac
MTTP expression, we combined clinical studies, advanced expression
analysis of human heart biopsies and analyses in genetically modified
mice. We show that MTTP polymorphisms in humans associate with
cardiac function in conjuction to ischemic events and are linked to
reduced MTTP expression. Our expression analyses reveal that MTTP in
the human heart is highly co-expressed with genes linked to cardiac
arrhythmias, mitochondrial function and lipid metabolism. Finally, we
show that knockout of Mttp-A in mice hearts reduces heart function
after a myocardial infarction despite compensatory upregulation of
Mttp-B. Together, these studies are consistent with the hypothesis that
MTTP plays an important role for heart function during ischemic
events.
2. Methods
2.1. The coronary flow reserve and cardiovascular events (CEVENT) study
In total, 441 patients with clinically suspected coronary artery dis-
ease (referred for investigation of chest pain) were recruited to parti-
cipate in the CEVENT study at the Department of Clinical Physiology,
Sahlgrenska University Hospital, Gothenburg, Sweden, from 2006 to
2008. Blood samples were taken after an overnight fast. All patients
underwent standard myocardial perfusion scintigraphy (MPS) for de-
tection of clinically meaningful myocardial ischemia and a complete
ultrasound examination of the carotid arteries within one month of the
MPS [32]. Ultrasound-based velocity vector imaging measurements
were processed later at a workstation. The presence of perfusion ab-
normalities was assessed using: (1) the summed stress score (the sum of
the segmental scores from the stress images), which reflects the extent
and severity of myocardial perfusion abnormalities related to both
myocardial ischemia and infarction; (2) the summed rest score (the sum
of the segmental scores assessed at rest), which represents the extent of
myocardial infarction; and (3) the difference between the first two (the
summed difference score), which represents stress-induced ischemia.
The absence and presence of left ventricle perfusion defects were scored
as 0 and>0, respectively.
For the present study, we excluded patients with overt ischemic
heart disease or who had undergone percutaneous transluminal cor-
onary angioplasty or coronary artery bypass grafting. Therefore, a total
of 310 patients with suspected coronary artery disease were included.
Of these MPS variables were analyzed in 309 subjects, and genotyping
of rs1800804(−164 T > C) polymorphism in 307 individuals.
The study was conducted in accordance with the Declaration of
Helsinki. All participants gave written informed consent, and the study
was approved by the local ethics committee in Gothenburg.
2.2. Genotyping of the CEVENT study population
Genomic DNA was isolated from whole blood. The rs1800804
(−164 T > C) polymorphism in the proximal promoter of MTTP was
genotyped by TaqMan technology using a premade assay
(C__11944682_20) according to the manufacturer's instructions
(Applied Biosystems). The call rate was>99%. Deviation from the
Hardy-Weinberg equilibrium was measured using the χ2 test.
2.3. The advanced study of aortic pathology (ASAP) study
The ASAP study was designed to investigate the development and
underlying causes, including genetic determinants, of valve disease and
ascending aortic dilation [33]. The study included patients undergoing
aortic valve surgery and/or surgery for aortic aneurysm at the Kar-
olinska University Hospital, Stockholm, Sweden Patients with coronary
artery disease were excluded. Fine needle biopsies from left ventricle of
the heart were taken during surgery and global gene expression mea-
sured using Affymetrix ST 1.0. RNA sequencing was performed in
biopsies from the left ventricle of the heart and liver biopsies in a subset
of eight patients to identify the presence of different MTTP isoforms.
Genotypes of the rs3816873 (Ile128Thr) polymorphism of MTTP were
determined from results obtained using Illumina Human 610 K chips
[33]. The study was conducted in accordance with the Declaration of
Helsinki. All participants gave written informed consent, and the study
was approved by the local ethics committee of the Karolinska Institute.
2.4. Mice
Genetically modified mice with heart-specific MTTP-A deficiency
were generated by breeding MTTP LoxP mice (B6;129S-
Mttp< tm2Sgy> /J, stock #3902, Jackson Laboratories) with alpha
myosin heavy chain (αMHC)-Cre mice (B6.FVB-Tg(Myh6-cre)
2182Mds/J, Jackson Laboratories) to obtain heart-specific Mttp-A
knockout (hMttp-A−/−) (n=30) and nontransgenic littermate litter-
mate controls (n=30). Identification of mice genotype was confirmed
by PCR of tissue extracts of the tail. The mice were kept under tem-
perature-controlled conditions with free access to food and water. The
experiments were approved by the ethics committee on animal ex-
periments in Gothenburg.
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2.5. Protein analysis in mouse hearts
Immunoblotting was done as described [34]. Briefly, proteins were
extracted from homogenized frozen mouse heart tissue with the
Qproteosome Mammalian Protein Prep Kit (Qiagen). Specific antibodies
for MTTP (kind gift from Prof L. Swift, Vanderbilt University, USA) and
Na+/K+ ATPase (Abcam) were used.
2.6. Analysis of gene expression in mouse hearts
Total RNA was isolated from homogenized heart tissue using
RNeasy Fibrous Tissue Mini Kit (Qiagen). cDNA was synthesized with
the high-capacity cDNA Reverse Transcription Kit (Applied Biosystems)
and random primers. mRNA expression of genes of interest was ana-
lyzed with TaqMan real-time PCR in an ViiA™ 7 system (Applied
Biosystems). The following specific TaqMan assays were used: Mttp-A
(5´CAGAGGGAGCCAGCATGATC, 3´GCAGAGTAGGAGGAGAAGAA
GCA, probe TCTTG GCAGTGCTTTT), Mttp-B (5´GGGTTTTGCGGGAAT
GGT, 3´CAACGCTTGACCGGGAAA, probe AGTGGCTACCGCGAGG),
Gfm2 (Mm00623824_m1), Hadh (Mm00492535_m1), Hprt
(Mm01545399_m1), Tmlhe (Mm00454748_m1) (Applied Biosystems).
2.7. MTTP activity in mouse hearts
Hearts from 10-week-old mice were homogenized in 1.5 ml buffer
[50mM Tris-HCl, 50mM KCl, 5 mM EDTA and protease inhibitor
(Roche) pH 7.4]. The heart homogenates were subjected to ultra-
centrifugation for 60min at 100000 g in a Beckman ultracentrifuge
(Beckman Coulter). The supernatant containing the microsomal frac-
tion was added to 1/10 volume of 0.54% sodium deoxycholate (pH 7.5)
and incubated on ice for 30min, followed by overnight dialysis at 4 °C
against a buffer (15mM Tris-HCl, 40mM NaCl, 10mM EDTA and
0.02% NaN3, pH 7.4). The protein concentration was measured using a
Pierce BCA protein assay kit (Thermo Scientific). The MTTP activity
was determined using MTTP Activity Assay Kit (Sigma Aldrich) ac-
cording to the manufacturer's protocol.
2.8. Lipid analyses of mouse hearts
Heart lipids from homogenized mouse hearts were extracted using
the BUME method [35], and analyzed using a QTRAP 5500 mass
spectrometry (Sciex). Cholesteryl esters, triglycerides and phospholi-
pids were analyzed using direct infusion (shotgun approach) with the
help of a robotic nanoflow ion source, TriVersa NanoMate (Advion
BioSciences) as described previously [36–39]. Ceramides were sepa-
rated using UPLC (Agilent Technologies) prior to mass spectrometric
detection according to previous work [40].
2.9. Induction of myocardial infarction and echocardiography in mice
A myocardial infarction was induced by ligating the left anterior
descending coronary artery immediately after the bifurcation of the left
coronary artery as described [34]. Echocardiography was performed at
baseline and 24 h after the myocardial infarction using the VisualSonics
VEVO 2100 system (VisualSonics) as described [34].
2.10. Statistical analyses
Statistical analyses were performed in SAS 9.3 (SAS Institute) and
the SPSS 19.0 software (SPSS). Allele frequency was tested for Hardy-
Weinberg equilibrium. Comparisons between continuous variables
were conducted using Student's t-test. Associations between single nu-
cleotide polymorphisms and continuous variables were tested under an
additive genetic model, using generalized linear models that can fit
heterocatanomic multivariate data (i.e., data that come from different
distributions) by the method of maximum likelihood. For ordinal
values, associations were tested by logistic regression analyses. The
models were adjusted for adjusted for age, sex, body mass index (BMI)
and triglycerides. Pearson's correlations were used to explore the re-
lationship between the expression levels of different genes. P va-
lues< .05 were considered significant. For the systems biology ana-
lyses, the human heart and liver data were retrieved from GTEx project
[41]. Genes that were differentially expressed between sample groups
were identified by performing a negative binomial test using DESeq2 R
package [42]. To identify differences between sample groups with re-
gard to biological processes, we also performed gene set enrichment
analysis using PIANO R package [43]. Global co-expression networks
were generated by calculating Pearson's correlation coefficient of ex-
pressions between all gene pairs [44].
3. Results and discussion
3.1. Human MTTP polymorphisms associate with cardiac function after an
ischemic event and reduced MTTP expression
To test if a genotype-specific MTTP expression in the myocardium
renders the heart particularly vulnerable to ischemic damage, we in-
vestigated if genetic variation in the MTTP-A promotor associates with
altered cardiac function during ischemia.
Of the 307 patients with suspected coronary artery disease (from the
CEVENT study) genotyped for the polymorphism rs1800804
(−164 T > C) in the MTTP-A promotor, 173, 114 and 20 subjects had
the genotypes TT, TC and CC, respectively (Table 1).
The minor allele frequency was 25.1% and the genotype distribu-
tion adhered to Hardy-Weinberg equilibrium (χ2= 0.044, P= .83).
Carriers of the minor e164C allele in MTTP had significantly higher
infarct score (β=0.974 ± 0.465, P= .036) and wall motion
(β=1.186 ± 0.388, P= .002) scores and a trend towards a higher
degree of stress-induced ischemia (indicated by summed difference
score) compared with subjects carrying the major allele (Table 2).
These results show that genetic variation of the human MTTP promotor
associated with cardiac dysfunction during stress-induced ischemia
detected by abnormal wall motion score, increased stress-induced
ischemia and clinical infarct scores.
MTTP is polymorphic, with several genetic variants in linkage dis-
equilibrium [45]. The MTTP-164 T > C (rs1800804) polymorphism is
in complete linkage disequilibrium with the MTTP Ile128Thr
(rs3816873) and MTTP-493G > T (rs1800591) polymorphisms [24].
Thus, all three polymorphisms act as markers for each other and all
have been shown to associate with increased risk of ischemic heart
disease [24,25,46]. An earlier study analyzed the relationship between
the MTTP-493G > T (rs1800591) promoter polymorphism and MTTP
expression in 18 heart muscle biopsies and found borderline results for
reduced cardiac MTTP expression [25]. Here we analyzed MTTP ex-
pression in heart biopsies from 126 patients (from the ASAP study)
genotyped for the polymorphism rs3816873 (Ile128Thr) and showed
that the minor allele of rs3816873 was associated with significantly
lower expression of MTTP in cardiomyocytes (Fig. 1).
3.2. Humans primarily express the MTTP-A isoform in the heart and liver
To identify whether different MTTP isoforms are expressed in the
heart, RNA sequencing of myocardial biopsies from the left ventricle
was performed in eight patients undergoing valve surgery. Liver biop-
sies from the same patients were also RNA sequenced and used as a
reference. As expected the RNA expression of MTTP in the heart was
much lower than the MTTP expression levels in the liver (Fig. 2). All
myocardial and liver biopsies that were RNA sequenced showed a
stronger signal for exon 1A compared with exon 1B. In fact, the ex-
pression signal from exon 1B in all samples did not differ from the
background signal (Fig. 2). This result shows that it is primarily the
MTTP-A isoform that is expressed in human heart and liver.
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3.3. Co-expression of genes with MTTP differs between human heart and
liver
Genes with coordinated expression across a variety of experimental
conditions may indicate the presence of functional linkages between
genes [47,48]. Therefore, to gain more understanding of the functional
role of MTTP in the human heart, we retrieved data from the Genotype-
Tissue Expression (GTEx) project [41]. First, we compared mRNA ex-
pression of MTTP in human heart (left ventricle, n=272) and liver
samples (n=156) and observed that MTTP expression was 60.6 times
lower in the heart than the liver (Supplementary Fig. 1). Genes that
collaborate in a shared function often require simultaneous expression.
We therefore identified genes whose expression was tightly associated
with MTTP in the heart and liver biopsies using the global co-expression
network (Supplementary Data 1), and showed that MTTP was asso-
ciated with different genes in the two tissues (Supplementary Tables 1
and 2), indicating that the functional roles of MTTP in the heart and
liver are different. In the heart, MTTP was highly co-expressed with
genes linked to cardiac arrhythmias (e.g. ryanodine receptor 2), mi-
tochondrial function and lipid metabolism. In the liver, the degree of
co-expression was weaker, and MTTP mainly co-expressed with genes
linked to different forms of metabolism. To analyze if MTTP is ex-
pressed in other cell types in the human heart, we collected cardiac
needle biopsies from the left ventricle as well as from epicardial fat
tissue from ischemic and non-ischemic patients and analyzed the ex-
pression of MTTP. The results confirmed that MTTP is expressed in
cardiac left ventricle biopsies, but virtually not detected in epicardial
fat biopsies (Supplementary Fig. 2). We also analyzed the expression of
MTTP in cultured fibroblasts, but were not able to detect any expression
Table 1
Characteristics of the study population in relation to anthropometric and cardiac parameters by rs1800804 (−164 T > C) genotype. The numbers of individuals
carrying each genotype are given in brackets at the top of the Table. TT indicates homozygosity for the major T allele, TC indicates heterozygosity and CC indicates
homozygosity for the minor C allele of the -164 T > C polymorphism. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TnT,
troponin; EF, ejection fraction; LVDD, left ventricle diastolic diameter; LVSD, left ventricle systolic diameter; PWT, posterior wall thickness; IVS, interventricular
septum; LVDV, left ventricle diastolic volume; LVSV, left ventricle systolic volume.
Variable TT (n=173) TC (n=114) CC (n=20)
n Mean ± sd n Mean ± sd n Mean ± sd
Age, years 173 60.8 ± 9.4 114 61.5 ± 8.4 20 60.1 ± 10.7
Men/women 69/104 41/73 7/13
BMI, kg/m2 173 26.4 ± 4.2 114 26.0 ± 4.0 20 27.0 ± 3.6
DBP, mmHg 170 84.6 ± 11.2 111 84.9 ± 11.5 20 87.1 ± 8.8
SBP, mmHg 173 143.6 ± 23.8 114 143.6 ± 21.5 20 144.0 ± 20.5
TnT, ng/ml 170 0.16 ± 0.07 114 0.17 ± 0.12 18 0.20 ± 0.11
Echocardiographic variables
EF, % 147 56.4 ± 6.4 97 54.4 ± 8.3 17 56.8 ± 6.1
LVDD, cm 164 4.5 ± 0.5 107 4.5 ± 0.5 18 4.7 ± 0.6
LVSD, cm 164 3.6 ± 0.5 107 3.6 ± 0.6 18 3.7 ± 0.6
PWT, cm 162 0.9 ± 0.1 104 0.8 ± 0.1 17 0.9 ± 0.1
IVS, cm 162 0.9 ± 0.1 102 0.9 ± 0.1 17 1.0 ± 0.1
LVDV, ml 147 83.1 ± 21.8 97 82.8 ± 25.3 17 86.4 ± 27.2
LVSV, ml 147 36.8 ± 13.8 97 38.7 ± 17.9 17 38.2 ± 18.0
Table 2
Association of MTTP rs1800804 (−164 T > C) polymorphism with MPS scores. Generalized linear models were used to explore the relationship between rs1800804
alleles and clinical MPS measurements expressed as ordinal scores. The absence and presence of left ventricle perfusion defects were scored as 0 and > 0, re-
spectively. The β-values refer to the effect of each additional copy of the minor allele with corresponding standard errors (se) and P values adjusted 1for age and sex,
and 2for age, sex, BMI and plasma triglyceride concentration.
MPS variable Score= 0 Score > 0 Per C allele effect
n (%) n (%) β se P value1 β se P value2
Infarct score 296 (95.8) 13 (4.2) 0.75 0.43 0.080 0.97 0.46 0.036
Ischemia score 215 (69.6) 94 (30.4) 0.21 0.20 0.196 0.22 0.21 0.281
Wall motion score 283 (93.09) 21 (6.9) 0.94 0.35 0.007 1.19 0.39 0.002
Summed rest score 107 (43.3) 140 (56.7) 0.26 0.24 0.286 0.21 0.25 0.392
Summed stress score 79 (31.5) 172 (68.5) 0.11 0.25 0.661 0.11 0.26 0.677
Summed difference score 129 (52.2) 118 (47.8) 0.45 0.22 0.040 0.43 0.23 0.058
Significant P-values are marked in bold.
Fig. 1. Cardiac human MTTP expression according to MTTP genotype. Cardiac
mRNA expression of MTTP as measured by gene expression array, according to
MTTP genotypes for rs3816873 (Ile128Thr), which is in complete linkage dis-
equilibrium with rs1800804 (−164 T > C). The bottom and the top of the box
indicates the interquartile range and the line represents the median. The
whiskers under and over the box correspond to the minimum and maximum
values. Major alleles denote homozygous for the major alleles (n=73); het-
erozygous (n=42); minor alleles denotes homozygous for the minor alleles
(n=11). The p-value denotes linear regression analysis of variance.
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(data not shown).
We next analyzed and compared the global gene expression in heart
biopsies from the quartiles with the highest (1.5 ± 0.4 transcripts per
million) and lowest (0.28 ± 0.12 transcripts per million) expression of
MTTP (n=68 for both). In total, 4562 genes showed significant dif-
ferences in expression (q value<0.01) between these two groups
(Supplementary Data 2). By performing gene set analysis for gene on-
tology (GO) biological process terms using the PIANO R package [43],
we found that heart biopsies with high versus low MTTP expression
showed: (1) significant upregulation of many heart muscle-related gene
sets (including regulation of cardiac muscle conduction, regulation of
heart rate, and regulation of cardiac muscle contraction); (2) significant
association with fatty acid metabolism-related GO biological process
terms (i.e., fatty acid, and monocarboxylic acid catabolic processes);
and (3) significant downregulation of immune and inflammatory re-
sponses (q value<1E-5 for all, Supplementary Data 3, Supplementary
Fig. 3). We also compared global gene expression in liver biopsies from
the quartiles with the highest (72.9 ± 17.0 transcripts per million) and
lowest (27.8 ± 8.1 transcripts per million) expression ofMTTP (n=39
for both). In total, 984 genes showed significant differences in expres-
sion (q value< 0.01) between these two groups (Supplementary Data
4). Gene set analysis showed, as expected, that lipid metabolism and
other central metabolism-related GO biological process terms were
significantly (q value< 1E-5) associated with high MTTP expression in
the liver biopsies (Supplementary Data 5, Supplementary Fig. 4). Im-
portantly, none of the gene sets associated with cardiac MTTP expres-
sion were significantly (q value<1E-5) enriched in the liver biopsies
with high versus low MTTP expression (Supplementary Data 5). Thus,
expression of MTTP in the heart seems to be linked to biological pro-
cesses that differ from those in the liver.
3.4. Knockout of Mttp-A in mice hearts does not affect lipid accumulation
but reduces heart function after a myocardial infarction
To test if MTTP-A influences cardiac lipid metabolism, gene ex-
pression of heart muscle-related genes, and stress responses after a
myocardial infarction, we generated heart-specific Mttp-A knockout
(hMttp-A−/−) mice using LoxP-Cre technology. We first showed that
hMttp-A−/− mice had normal hepatic Mttp-A mRNA expression
(131.4 ± 37.5% of nontransgenic littermates at baseline), but lacked
cardiac expression of Mttp-A mRNA both at baseline and after a myo-
cardial infarction (Fig. 3A). However, cardiac MTTP protein levels did
not differ between the hMttp-A−/− mice and their littermate controls
either at baseline or after a myocardial infarction (Fig. 3B). Further-
more, hMttp-A−/− mice had normal MTTP activity (94.4 ± 10.4% of
nontransgenic littermates at baseline). These results indicated
Fig. 2. RNA sequencing of the MTTP gene in human myocardial and liver biopsies. Representative expression signals from RNA sequencing analyses of non-ischemic
human biopsies from the left ventricle of the heart and from the liver obtained from three patients undergoing heart valve surgery. At the top the MTTP gene is
depicted with the putative exons indicated. The intensities of the signals are given to the left. Subject 114 is homozygous for the minor allele, subject 167 is






































































































Fig. 3. Mttp heart expression at baseline (Ctrl) and 24 h after
MI in heart-specific Mttp-A knockout mice and their litter-
mate controls. mRNA (normalized to Hprt) and MTTP protein
(normalized to Na+/K+ ATPase) levels in the heart from
Mttp-A heart-specific knockout mice before and after a
myocardial infarction. (A) Values are mean ± SEM
n=8–10. (B) Values are mean ± SEM n=4–5. Unfilled
bars denote nontransgenic littermates and filled bars heart-
specific Mttp-A knockout mice. *P < .05, **P < .01,
***P < .001.
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compensatory upregulation of other MTTP isoforms in hMttp-A−/−
mice. Indeed, expression analysis showed that the expression of Mttp-B
was upregulated in the heart of hMttp-A−/− mice both at baseline and
after a myocardial infarction (Fig. 3C). Thus, heart-specific Mttp-A de-
ficiency did not result in reduced cardiac total MTTP activity, due to
compensatory upregulation of the Mttp-B. These results are in agree-
ment with an earlier study showing increased expression of Mttp-B in a
heart-specific Mttp-A knockout mouse model [8].
We next tested if the compensatory upregulation of Mttp-B would be
sufficient for heart function to be maintained in hMttp-A−/− mice after
an experimental myocardial infarction. As expected, cardiac accumu-
lation of neutral lipids and ceramide species was increased in mice 24 h
after a myocardial infarction (Fig. 4A and B). However, no differences
in cardiac lipid content were observed between the heart-specific Mttp-
A−/− mice and their littermate controls either at baseline or 24 h after
the experimental myocardial infarction (Fig. 4A and B). We also per-
formed a more detailed analyses of different ceramide species. Results
showed very similar patterns of the heart ceramide species (Supple-
mentary Fig. 5).
Echocardiogram analysis revealed that the Mttp-A−/− mice dis-
played a normal ejection fraction (i.e., a measure of the pumping effi-
ciency of the heart) at baseline but a reduced ejection fraction 24 h after
a myocardial infarction (Fig. 5A and B). These results indicate that
Mttp-A−/− mice display impaired cardiac function after a myocardial
infarction despite maintaining normal cardiac lipid equilibrium.
3.5. Reduced cardiac expression of heart muscle-related gene in heart-
specific Mttp-A−/− mice
In our expression analysis of human heart biopsies, we identified a
set of upregulated genes linked to mitochondrial function whose ex-
pression was tightly associated with MTTP in the human heart
(Supplementary Table 1). We therefore investigated expression of three
of these mitochondrial genes in hearts from Mttp-A−/− mice at baseline
and after an experimental myocardial infarction. We showed that these
mitochondrial genes were significantly, although modestly, down-
regulated in hMttp-A−/− mice at baseline (Fig. 6). However, only
Tmhle, that encodes the mitochondrial epsilon-N-trimethyllysine
hydroxylase, an important regulator of carnitine biosynthesis and
transport of fatty acids across the inner mitochondrial membrane [49],
was significantly downregulated after a myocardial infarction (Fig. 6).
We also analyzed the expression of additional enzymes and transporters
associated with fat uptake into the cardiomyocytes in heart biopsies
from nontransgenic littermates and heart-specific Mttp-A knockout
mice (Supplementary Fig. 6). No significant differences were detected
between MTTP-A deficient mice or littermate control mice, before or
after an experimental MI (Supplementary Fig. 6).
4. Conclusion
Epidemiology studies have linked a minor allele of a promoter
polymorphisms in MTTP that results in lower gene expression to in-
creased risk of ischemic heart disease independent of plasma lipids.
However, the underlying mechanism(s) are still unclear. Here we have
tested the hypothesis that MTTP plays an important role for heart
function during ischemic events. We show that this functional human
MTTP promoter polymorphism is associated with cardiac dysfunction
during stress-induced ischemia. Our expression analyses demonstrated
that many heart muscle-related gene sets were significantly upregulated
in heart biopsies with high MTTP expression, and that the expression
profile of MTTP differs between the heart and liver. Finally, we show
that knockout of Mttp-A in mice hearts reduced heart function after a
myocardial infarction despite compensatory upregulation of Mttp-B and
no effect on lipid accumulation. Together, these studies indicate that
MTTP likely plays an important role for heart function after an ischemic
event. However, the underlying mechanism(s) are still unclear. Our
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Fig. 4. Lipid content (normalized to phosphatidylcholine (PC)) in the hearts of
hMTTP−/− mice and their littermate controls at baseline and 24 h after myo-
cardial infarction (MI). A, Neutral lipids and phospholipids levels in the heart at
baseline (Ctrl) and 24 h after MI. B, Ceramide species levels in the heart at
baseline (Ctrl) and 24 h after MI. Unfilled bars denote nontransgenic littermates
and filled bars heart-specific Mttp-A knockout mice. Data are mean ± SEM,





































Fig. 5. Heart function as measured by echocardiography at baseline (Ctrl) and
24 h after MI in hMTTP−/− mice and their littermate controls. A, Ejection
fraction at baseline (Ctrl) and 24 h after MI. B, Differences in ejection fraction
post MI compared with baseline. Unfilled bars denote nontransgenic littermates
and filled bars heart-specific Mttp-A knockout mice. Data are mean ± SEM,
n=7–9, *P < .05
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Fig. 6. mRNA expression (normalized to Hprt) in the heart from Mttp-A heart
specific knockout mice before and after a myocardial infarction. Tmhle, tri-
methyllysine hydroxylase, epsilon; Hadh, hydroxyacyl-CoA dehydrogenase;
Gfm2, G elongation factor mitochondrial 2; Hif1α, hypoxia-inducible factor 1-
alpha. Data are mean ± SEM, n=7–9, *P < .05, **P < .01, ***P < .001.
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results link MTTP to mitochondrial function, and the physiological/
pathophysiological relevance of this needs to be tested in future studies.
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